M. Domagała-Haduch, J. Wnuk, Ł. Michalecki, I. Gisterek
{"title":"中性粒细胞与淋巴细胞比率作为姑息性治疗胰腺导管腺癌患者的预后因素","authors":"M. Domagała-Haduch, J. Wnuk, Ł. Michalecki, I. Gisterek","doi":"10.5603/njo.a2023.0009","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":130080,"journal":{"name":"Nowotwory. Journal of Oncology","volume":"68 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neutrophil-to-lymphocyte ratio as a prognostic factor in patients during palliative treatment of pancreatic ductal adenocarcinoma with a FOLFIRINOX regimen\",\"authors\":\"M. Domagała-Haduch, J. Wnuk, Ł. Michalecki, I. Gisterek\",\"doi\":\"10.5603/njo.a2023.0009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":130080,\"journal\":{\"name\":\"Nowotwory. Journal of Oncology\",\"volume\":\"68 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nowotwory. Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/njo.a2023.0009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nowotwory. Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/njo.a2023.0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Neutrophil-to-lymphocyte ratio as a prognostic factor in patients during palliative treatment of pancreatic ductal adenocarcinoma with a FOLFIRINOX regimen